A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

Clinical trial NCT06677307 · TERMINATED

Trial details

NCT number: NCT06677307
Sponsor: Korro Bio, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Alpha-1 Anti-trypsin Deficiency AATD

Start date: 2025-01-13
Primary completion: 2025-10-31
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.